C024P: Atezolizumab Biosimilar, PD-L1 Monoclonal Antibody
Recombinant Humanized IgG1 Monoclonal Antibody.
Specificity/Sensitivity: The in vivo grade atezolizumab biosimilar specifically binds to the human PDL1 protein.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by atezolizumab.C038P: Ustekinumab Biosimilar, IL-12 / IL-23 Monoclonal Antibody
Recombinant Humanized IgG1 Monoclonal Antibody.
Specificity/Sensitivity: The in vivo grade ustekinumab biosimilar specifically binds to the human interleukin-12 (IL-12) and interleukin-23 (IL-23).
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by ustekinumab.C031P: Nimotuzumab Biosimilar, EGFR Monoclonal Antibody
Recombinant Humanized IgG1 Monoclonal Antibody.
Specificity/Sensitivity: The research grade nimotuzumab biosimilar specifically binds to the human epidermal growth factor receptor (EGFR).
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by nimotuzumab.C074P: Semaglutide Biosimilar
Source: The recombinant peptide semaglutide biosimilar was produced in the semaglutide stable cell line.
Applications: ELISA, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by semaglutide.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.C073P: Liraglutide Biosimilar
Source: The recombinant peptide liraglutide biosimilar was produced in the liraglutide stable cell line.
Applications: ELISA, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by liraglutide.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.C075P: Etanercept Biosimilar
Recombinant protein composed of the soluble TNF receptor 2 fused with the Fc region of human immunoglobulin gamma 1 (hIgG1).
Specificity/Sensitivity: The etanercept biosimilar protein specifically binds to the human TNF alpha.
Applications: Functional assays, and those assays for studying biological pathways affected by etanercept.C037P: Tremelimumab Biosimilar, CTLA-4 monoclonal antibody
Recombinant Chimeric IgG2 Monoclonal Antibody.
Specificity/Sensitivity: The in vivo grade tremelimumab biosimilar specifically binds to the human protein receptor CD152 / CTLA4.
Applications: ELISA, neutralization, in vivo functional assays such as bioanalytical PK and ADA assays, and those in vitro and in vivo assays for studying biological pathways affected by tremelimumab.C035P: Spartalizumab Biosimilar, PD-1 Monoclonal Antibody
Recombinant Humanized IgG4 Monoclonal Antibody.
Specificity/Sensitivity: The in vivo grade spartalizumab biosimilar specifically binds to the programmed cell death protein 1 (PD-1), antagonizing its interaction with its known ligands PD-L1 and PD-L2.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by spartalizumab.C055P: Natalizumab Biosimilar, Integrin alpha 4 Monoclonal Antibody
Recombinant Humanized IgG4 Monoclonal Antibody.
Specificity/Sensitivity: The in vivo grade natalizumab biosimilar specifically binds to the human Integrin α4.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by natalizumab.C054P: Muromonab Biosimilar, CD3 Monoclonal Antibody
Recombinant mouse IgG2a Monoclonal Antibody.
Specificity/Sensitivity: The in vivo grade muromonab biosimilar specifically binds to the human T cell receptor CD3.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by muromonab.